27 results on '"Borzio M."'
Search Results
2. Therapeutic Strategies in the Real Life in BCLC-C Hepatocellular Carcinoma in Italy: Assessment in the Italian Liver Cancer and Validation in the Italian Association of Hospital Gastroenterologists Database
3. FRI-094 - External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study
4. SAT-099 - Therapeutic Strategies in the Real Life in BCLC-C Hepatocellular Carcinoma in Italy: Assessment in the Italian Liver Cancer and Validation in the Italian Association of Hospital Gastroenterologists Database
5. 671 CLINICAL FEATURES OF NON ALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC) IN ITALY: A MULTICENTER PROSPECTIVE SURVEY
6. 252 IMPROVING PROGNOSIS OF HCC IN THE REAL-WORLD CLINICAL PRACTICE: AN ITALIAN EXPERIENCE
7. 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS
8. 522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY
9. 1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS
10. 916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY
11. 475 Sustained virological response (SVR) to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC)
12. Peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
13. Combination of interferon alpha and ribavirin in chronic hepatitis C non responders to interferon monotherapy: role of genotype and age
14. IFN alpha 2b and ribavirin in naive patients with HCV type 1 chronic hepatitis: results after 6 months of therapy
15. Iron depletion and interferon (IFN) therapy: A multicenter, randomized trial in “naive” patients with chronic hepatitis C
16. Short-term prognosis of bacterial infection in hospitalized cirrhotic patients
17. Histological variables predictive of hepatocellular carcinoma (HCC) in patients with genetic hemochromatosis (GH)
18. Spontaneous bacterial peritonitis (SBP) in 200 ascitic cirrhotics: Prevalence, Outcome and recurrence
19. Is serum alpha-fetoprotein (AFP) useful in early diagnosis of hepatocellular carcinoma (HCC)? A prospective study
20. HBV-DNA fluctuation in anti-HBe positive chronic hepatitis B
21. Liver cell dysplasia(LCD)in cirrhosis is a major risk factor for hepatocellular carcinoma (HCC): A prospective study
22. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C
23. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis
24. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis
25. HBV-DNA fluctuation in anti-HB e positive chronic hepatitis B
26. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development.
27. Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.